Robert Orlowski, Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared on X:
“Myeloma Paper of the Day:
Dual BCMA and GPRC5D targeting w/ trispecific mAb ramantamig addresses antigenic heterogeneity in myeloma, probably due to higher avidity against heterogeneous targets; less affected by soluble BCMA vs mono-targeting abs.”
Title: Dual targeting of BCMA and GPRC5D with the trispecific antibody ramantamig addresses antigenic heterogeneity in myeloma
Authors: David F. Moreno, Ferran Nadeu, Marta Casado-Peláez, Caterina Mata, Ian Márquez-López, Marco A. Fernández, Sergi Vaqué, Elena Medina, Helena Llobregat, Marta Garrote, Joan Mañé, Oriol Cardús, Luis Gerardo Rodríguez-Lobato, Anna de Daniel, María Teresa Cibeira, Theo Gremen Oliveira, Elizaveta Kulaeva, Ester Lozano, Dolors Colomer, Laura Rosiñol, Ruben van Boxtel, Manel Esteller, Carlos Fernández de Larrea
You can read the full article on HemaSphere.
You can find other articles featuring Robert Orlowski on OncoDaily.
